Brings extensive health insurance and biotech experience WASHINGTON, DC (September 2, 2025) – The Association for Accessible Medicines today welcomes Alex Keeton as the Executive
Mark your calendar for February 23–25, 2026, and join us at the JW Marriott Miami Turnberry Resort & Spa for a can’t-miss event bringing together
AAM Congratulates Dr. Tidmarsh on Appointment as Director of CDER WASHINGTON (July 21, 2025) — The Association for Accessible Medicines and the Biosimilars Council today
Expanded capacity adds to current fill and finish products already 100% manufactured in U.S. WASHINGTON, DC (July 15, 2025) – The Association for Accessible Medicines
Beginning in 2026, the Inflation Reduction Act (IRA) will usher in a new era of federal price setting on select high-cost prescription drugs. The program
Matrix Global Advisors analysis shows quantifiable negative impact and a less competitive marketplace with potential lost savings of billions per year WASHINGTON (July 14, 2025)
White paper analyzes problems and solutions to patent abuses WASHINGTON (July 8, 2025) — The Association for Accessible Medicines and its Biosimilars Council today released
39 Groups support the Biosimilar Red Tape Elimination Act WASHINGTON (July 8, 2025) — The Biosimilars Council and the Association for Accessible Medicines today sent
Brings over twenty years of legislative and policy experience WASHINGTON (July 7, 2025) — The Association for Accessible Medicines today welcomes Mark Ratner as Senior
WASHINGTON, DC (June 30, 2025) – The Association for Accessible Medicines today commented on the announcement by Hikma Pharmaceuticals USA to invest $1 billion to
A Minnesota law was found by the district court and appeals court to unlawfully regulate prices in other states WASHINGTON, DC (June 12, 2025) –
This month, the Association for Accessible Medicines and its Biosimlars Council issued a report based on research and analysis undertaken by the IQVIA Institute for
